10th Annual Neuroscience Innovation Forum

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

10th of January 2027|MARINES' MEMORIAL CLUB | SAN FRANCISCO | USA

Keynote Speakers:

Harry Tracy

President, NI Research Inc.

Dr. Tracy's background includes thirty years of experience as a clinician and consultant in a variety of psychiatric and neurological settings. He received his PhD from the University of Miami, and completed his clinical training at Massachusetts General Hospital/Harvard Medical School. In 1995, Dr. Tracy founded NI Research, which has provided analysis and candid commentary for neurotherapeutics companies and investors for three decades via its flagship publication, NeuroPerspective.

Industry Overview Keynote SpeechSun, 10 JanKeynote Speech Sun, 10 Jan

Speakers:

Aaron Nelson

Partner, Venture Investments, Novo Holdings US Inc.

Profile coming soon...

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Alex Colville

General Partner, Age1 Capital Management, LLC

Profile coming soon...

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Alexander Gebauer

Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc.

Dr. Gebauer has more than 30 years of industry experience in research and development and has been part of teams responsible for numerous approvals worldwide in several therapeutic areas, including Alzheimer’s disease. He served as CEO of Secarna Pharmaceuticals; CEO and Chairman at Omeicos Ophthalmics Inc, Cambridge, MA, USA; and as CDO and Managing Director of the Berlin, Germany-based sister company, Omeicos Therapeutics. He has held C-level positions at leading global pharmaceutical firms, including Sun Pharmaceuticals and Merz Pharmaceuticals. During his time at Merz, he served as Senior Vice President, Head of Global Research & Development, and was directly involved in the development of memantine, which was approved for the treatment of Alzheimer’s. Dr. Gebauer studied medicine at Johannes Gutenberg University, Mainz, Germany, where he also earned a PhD in experimental pharmacology. He additionally holds a degree in computer science and has lectured on pharmaco-economics.

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Amit Etkin

Founder & CEO, Alto Neuroscience Inc.

Dr. Amit Etkin is the Founder and CEO of Alto Neuroscience, a clinical-stage biotechnology company pioneering precision psychiatry. Dr. Etkin is a trained psychiatrist, neuroscientist, and served on Stanford University’s faculty for over a decade before launching Alto out of his research lab. As a tenured Professor, Dr. Etkin became an international leader in the neuroscience of psychiatric disorders and their treatments, receiving an NIH Director’s Pioneer Award for precision psychiatry work. He has a proven track record of success with publications in high-impact journals, raising extensive private and public funding, and managing a large and diverse team of scientists, clinicians, and engineers towards a shared scientific vision. Dr. Etkin took Alto public on the NYSE (ANRO), and also received an EY Entrepreneur of the Year award.

The Neuropsychiatry Renaissance Panel: New Targets, New TherapiesSun, 10 Jan

Anna Lisa Picciolo-Lehrke

Head of Business Development Neurology, UCB Pharma

Anna Lisa Picciolo-Lehrke is Head of Business Development Neurology at UCB, where she drives strategic growth through acquisitions, licensing, and partnerships across innovative therapeutic modalities. Over her 20+ year career, she has led and negotiated transactions spanning therapeutics, diagnostics, and digital health, contributing to major deals including the acquisitions of Neurona Therapeutics, Zogenix, Ra Pharmaceuticals, and Engage Therapeutics.

Before joining UCB, Anna Lisa held business development roles at Schwarz Pharma and the German Cancer Research Center (DKFZ), where she managed intellectual property and commercialization strategies for pioneering research innovations. She holds a PhD in Biology from DKFZ and is a Board Member of the Pharma Licensing Club Germany (PLCD) and a Board Observer at Grin Therapeutics, Inc.

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Avram Fraint

Senior Director, Clinical Science & External Affairs, Aspen Neuroscience, Inc.

Profile coming soon...

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 Jan

Bruce Leuchter

President & CEO, Neurvati Neurosciences, Inc.

Dr. Bruce Leuchter is President, CEO, and board member of Neurvati Neurosciences and GRIN Therapeutics. A physician by training and neuropsychiatrist by specialty, he brings deep expertise in clinical research, patient care, and the development of novel therapies for neurological and psychiatric disorders.

Prior to his work as a biotech executive, Dr. Leuchter held senior roles for over a decade in biotechnology equity research at Goldman Sachs, healthcare investment banking at Credit Suisse, and mergers and acquisitions at PJT Partners, where he provided strategic and capital markets advisory to leading biopharmaceutical companies.

Dr. Leuchter served as the Director of Clinical Neuropsychiatry at Weill Cornell Medical College, where he currently holds a voluntary faculty appointment. He is a co-founder and the founding neuropsychiatrist of Click Therapeutics. He serves on the board of Arrivo BioVentures and Courage Therapeutics, is a member of the Scientific Advisory Committee for the Daedalus Fund for Innovation at Weill Cornell, and sits on the Life Sciences Institute Leadership Council at the University of Michigan.

The Neuropsychiatry Renaissance Panel: New Targets, New TherapiesSun, 10 Jan

Carla Lema Tomé

Head of Neuroscience Search & Evaluation, AbbVie, Inc.

Profile coming soon...

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Celine Bouquet

Global SnE Head and Basel BD Head, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche AG

Celine Bouquet is a business development leader with over 15 years of experience in neuroscience, ophthalmology, and rare diseases. As Global SnE Head and Basel BD Head, Neuroscience, Ophthalmology and Rare Diseases, she leads deal-making, licensing, and strategic collaborations to accelerate innovation and expand the company’s pipeline. She has played a pivotal role in advancing partnerships with biotech and academic institutions, from early discovery through late-stage development.

An Ecole Normale de Lyon fellow, she holds a PhD in Neuroscience from Université Pierre et Marie Curie and completed postdoctoral research in ophthalmology at UCSF before moving into R&D and business development. Over her career, she has built strong strategic and operational expertise, leading due diligence, licensing, and M&A activities that have shaped Roche’s research and development portfolio.

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Chris Stern

Managing Director, L.E.K. Consulting

Christopher Stern is a Managing Director and Partner in L.E.K.’s Life Sciences practice and is based in the Boston office. He works with clients across the life sciences industry, from large pharmaceutical companies to emerging biotechnology firms, helping them navigate complex challenges and develop strategies for asset, therapeutic area, and corporate growth. His expertise spans therapeutic areas with rapidly evolving standards of care, with extensive experience in ophthalmology, central nervous system (CNS) disorders, and cardiometabolic disease.

Chris joined L.E.K. in 2013 as a Life Sciences Specialist and has since advised clients on critical strategic initiatives. From 2021 to 2023, he worked at UPMC Enterprises, the innovation and investment arm of UPMC. While there, he served as founding Chief Business Officer for Avista Therapeutics, a portfolio company focused on developing next-generation gene therapies for blinding diseases.

Chris earned his Ph.D. in Neuroscience from the University of Minnesota, where he studied novel molecular mechanisms of neuronal stress peptides. He completed postdoctoral training in neurology and epilepsy at Stanford University School of Medicine. He also holds a B.S. in Biochemistry, graduating summa cum laude, from Saint Vincent College in Pennsylvania.

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 Jan

Chris Hoyt

CEO, KeifeRx LLC

Profile coming soon...

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Daniel Lee

Partner, PJT Partners

Daniel Lee is a Partner in the Strategic Advisory Group at PJT Partners, based in New York. Dan is a founding member of the PJT Healthcare team leading life science engagements and acting as a trusted strategic and M&A advisor to executive management teams and boards of directors on complex matters in the Large Cap Pharma and Biotech sectors.

Prior to joining PJT Partners, Mr. Lee worked in the investment banking divisions of Goldman Sachs and Morgan Stanley where he advised clients across multiple industries in mergers & acquisitions, leveraged buyouts and activism defense mandates.

Mr. Lee graduated cum laude from Northwestern University where he was elected to Phi Beta Kappa and received his JD from NYU School of Law.

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Diana Saraceni

Co-Founder & General Partner, Panakès Partners SGR SpA

Diana Saraceni is Co-Founder & General Partner at Panakes, a Venture Capital firm dedicated to early-stage investments in Life Sciences primarily in Europe and the US. With over 20 years of Venture Capital experience, she has also co-founded and managed 360 Capital Partners, another leading pan-European Venture Capital firm. She has led investments in a significant number of companies all over Europe and in the US, not only in the Life Sciences sector, and generated several exits as IPO and M&A transactions. Diana is also part of several committees in Europe and in the US for public/private grants and awards allocation to start-ups. She also follows several portfolios in neuroscience, oncology, endoscopy, tissue regeneration, ophthalmology and pain.

New Directions in Neurotechnology Panel: Devices, Therapeutics & WellnessSun, 10 Jan

Gaia Skibinski

VP & Head of Translational Therapeutics, The Michael J. Fox Foundation for Parkinson's Research

Gaia Skibinski, PhD, is VP and Head of Translational Therapeutics at The Michael J. Fox Foundation for Parkinson's Research (MJFF). She oversees the Foundation's translational therapeutics strategy, including the Therapeutics program, which accelerates the development of Parkinson's disease therapies, and the Targets to Therapies initiative, which de-risks and advances emerging therapeutic targets. In this role, she partners across academia, biotechnology, and the pharmaceutical industry to accelerate innovative drug discovery, reduce barriers to therapeutic development, and catalyze investment in Parkinson's disease research.

Before joining MJFF, she served as SVP of Biology at Herophilus, where she helped build the company's human cerebral organoid platform from its inception through its acquisition by Roche and Genentech. She also led scientific strategy and discovery programs spanning Parkinson's disease, Rett syndrome, Alzheimer's disease, and schizophrenia.

Previously, at the Gladstone Institutes, she established pioneering human cellular models to investigate the roles of LRRK2 and alpha-synuclein in neurodegeneration, creating a Parkinson's disease drug discovery platform that enabled high impact collaborations with partners including Amgen, Biogen, Merck, Google Accelerated Science, and Verily.

She earned her BA in Biological Sciences from Magdalen College, University of Oxford, and her PhD from the UCL Institute of Neurology in London, where she identified CHMP2B as a causative gene for frontotemporal dementia.

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 Jan

Gregor Macdonald

VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S

Since August 2021, Gregor has been VP and Head of BD & Licensing, Search and Assessment at Lundbeck. In this role, he and his team are responsible for the global search, scientific evaluation and business case support of assets, research programs and technologies from early research to late clinical development and commercial stages. Prior to this role, Gregor spent 5 years as Senior Director of Scientific Licensing (Neuroscience), within Janssen Business Development, the pharmaceutical companies of J&J, leading the identification and evaluation of clinical stage assets and companies for licensing and M&A. Before moving into Business Development, Gregor was Head of Neuroscience Medicinal Chemistry EU at Janssen for 12 years, where he led discovery teams in Belgium and Spain towards the identification of clinical drug candidates in the areas of Alzheimer’s disease, schizophrenia and depression. In addition, Gregor was also extensively involved in identifying external drug discovery opportunities and prosecuting research collaborations with a variety of academic, biotech and pharma partners. Gregor started his career within the Medicinal Chemistry depts. of SmithKline Beecham and GlaxoSmithKline, where he spent 7 years in the Neuroscience area. Gregor is a co-author and co-inventor on over 110 scientific publications and patents and has been an invited speaker and panelist at several international conferences.

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Jackie von Salm

Co-Founder & Chief Scientific Officer, Psilera Inc.

Dr. Jackie von Salm is a scientist with 15 years of experience in drug discovery and innovation. She holds her Ph.D. in Chemistry from the University of South Florida. During her time in academia, she explored exotic environments, from Antarctica to the Caribbean, in search of new chemistry and natural medicines.

Dr. von Salm has been featured in National Geographic, Nature, and the Wall Street Journal, and was named the Most Read Author in 2017 by the American Chemical Society.

Dr. Jackie von Salm co-founded Psilera in 2019, a biotechnology company focused on discovering neuroplastogen-based treatments for brain health. Psilera successfully licensed part of its patent portfolio to ataiBeckley in a strategic deal that demonstrates the commercial value of novel psychedelic compounds.

Psychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

Jay Olson

Managing Director & Senior Analyst, Oppenheimer & Co. Inc.

Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an M.B.A. in Finance and an M.S. in Chemical Engineering both from MIT, and a B.S. in Chemical Engineering from Tufts University. He also holds the CFA designation.

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 JanLongevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Jeff Cohen

Director of Research, Ladenburg Thalmann & Co. Inc.

Mr. Cohen is responsible for equity research coverage of medical technology and healthcare services. He has 20 years of experience directly involved in the worldwide financial markets, of which he has spent the past 11 years directly involved in healthcare research and sales.

Prior to joining Ladenburg Thalmann, he was a Senior Healthcare Research Analyst at C.K. Cooper & Company focusing upon the biotechnology, medical technology, and healthcare services segments. Mr. Cohen also served as a healthcare research analyst at Jesup & Lamont Inc., where he focused on medical technology with sector specialization within Cardiology, Vascular, Orthopedics, and Diabetes. Prior to equity research & sales, he spent seven years trading and managing fixed‐income and equity derivative products at Cantor Fitzgerald, Sanwa Securities and the American Stock Exchange.

Mr. Cohen holds a B.S.E. in Systems Engineering from the University of Pennsylvania and an M.B.A. from the University of Miami. He has also served as an Adjunct Professor of Business & Management at Lynn University, teaching Economics, Management, and International Business.

New Directions in Neurotechnology Panel: Devices, Therapeutics & WellnessSun, 10 Jan

Jim Ray

Executive Director, Neuroscience, UT MD Anderson

Jim Ray, PhD is the Director of The Belfer Neurodegeneration Consortium (BNDC), a multi-institutional collaboration whose mission is to slow, stop, or reverse Alzheimer’s disease and related neurodegenerative disorders, and Founding Co-Director of MD Anderson’s Cancer Neuroscience Program. The BNDC is a collaboration between six leading institutions, including MIT, Mt Sinai School of Medicine, Baylor, Brown, and NYU. Prior to joining the NDC in April 2015, Dr. Ray was Director, CNS Research at Takeda Pharmaceuticals, and led several drug discovery projects from basic research into development for schizophrenia, Parkinson’s disease, autism, and depression. He joined Takeda in 2013 as part of their acquisition of the biotech start-up Envoy Therapeutics, where he was Senior Director and responsible for developing both a pipeline of CNS therapeutics as well as a platform technology. Prior to Envoy Therapeutics, Dr. Ray spent 11 years at Merck, where he led multiple research projects in Alzheimer’s disease. He earned his PhD from Washington University Medical School in Neuroscience and has 72 publications and 25 patents.

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Joseph Tucker

CEO, Enveric BioSciences, Inc.

Dr. Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.

Psychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

Kabir Nath

CEO, Compass Pathways

Kabir Nath joined Compass Pathways as Chief Executive Officer in August 2022. Kabir is a purpose-driven leader with a strong personal connection to the challenges of serious mental illness and to Compass’s mission.

With more than thirty years of biopharmaceutical and medical technology experience, Kabir has shaped strategy and delivered results in complex, challenging business environments at the country, regional, and global level; he has lived and worked in several countries across Europe and Asia, as well as the USA. He is currently based in London.

Prior to joining Compass, Kabir held senior leadership positions at Otsuka Pharmaceutical Company and Bristol Myers Squibb; previously he held a number of operational and strategic roles at the medical technology company Smith & Nephew. Kabir has an MA from the University of Cambridge and an MBA with Distinction from INSEAD.

Psychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

Karen LaRochelle

SVP, Global Business Development & Strategy, Merz Therapeutics GmbH

Karen LaRochelle is an accomplished executive with over 30 years of experience in biopharma strategy and transactions. As Senior Vice President at Merz Therapeutics, Karen leads Global Business Development and Strategy, overseeing partnerships, strategic alliances, and long-term strategic direction. Previously, Karen held Chief Business Officer roles at several biotechnology firms focused on oncology, immunology, and neuroscience, where Karen advanced innovative therapies and key partnerships. Earlier, Karen spent two decades at Bristol-Myers Squibb, executing more than 50 major transactions across research, development, and commercial functions, significantly enhancing the company’s portfolio and forging high-value collaborations. Karen holds an MBA from Columbia University and a Bachelor of Science in Industrial Engineering from Lehigh University, where Karen serves as Chair of the P.C. Rossin School of Engineering Advisory Board.

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 Jan

Ken Mariash

CEO, Sinaptica Therapeutics, Inc.

As CEO of Sinaptica, Ken is leading the team to advance their personalized closed-loop neuromodulation therapy for Alzheimer's, which has generated very positive sham-controlled clinical data from two phase 2 trials both published in top peer-reviewed journals. Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target-- the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company is now in-process on financing to initiate a pivotal study.

Previously to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development.

At Boston Scientific's nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire. He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications.

New Directions in Neurotechnology Panel: Devices, Therapeutics & WellnessSun, 10 Jan

Klaus Dugi

CEO, Vandria SA

Klaus, CEO and board member of Vandria, brings over 18 years of leadership in top 50 pharma companies, including 9 years as CMO at Boehringer Ingelheim and Ferring. He has overseen the development and launch of four blockbuster drugs and holds 17 patents. In addition to his commercial experience as GM, he serves on the boards of AOBiome and Ferring Ventures, and is an Adjunct Professor of Medicine at Heidelberg University.

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Laszlo Kiss

CBO & Head of Research, Gilgamesh Pharmaceuticals

Laszlo Kiss is the Chief Business Officer and Head of Research at Gilgamesh Pharmaceuticals, with over 25 years of experience in drug discovery, development, venture capital, and management. He has a strong track record of leading drug discovery programs for central nervous system (CNS), cardiovascular (CV), and rare diseases, guiding projects from early-stage research through clinical development.

Before joining Gilgamesh, Laszlo held positions of increasing responsibility at Pfizer, Biogen, Bristol-Myers Squibb, Essen Biosciences, and Merck & Co. He earned his Ph.D. in Physiology and Neurobiology from the University of Connecticut and completed postdoctoral training in Neuroscience at the University of California, San Diego.

He is the author of more than 50 scientific publications in peer reviewed journals, book chapters, abstracts and patents. Laszlo has served on grant review panels at the National Institutes of Health, National Institute of Neurological Disorders and Stroke.

The Neuropsychiatry Renaissance Panel: New Targets, New TherapiesSun, 10 Jan

Laura Nisenbaum

Interim Chief Science Officer, Alzheimer's Drug Discovery Foundation

Laura Nisenbaum, PhD, is the Interim Chief Science Officer at the Alzheimer’s Drug Discovery Foundation (ADDF), where she leads a team of scientists driving the organization’s mission to transform the future of diagnosis, treatment, and prevention for Alzheimer’s and other dementias. She oversees ADDF’s three interdependent scientific pillars: Therapeutics, advancing innovative, biomarker-driven strategies beyond amyloid to target novel mechanisms; Biomarkers, accelerating discovery and validation to enable earlier, more precise detection and guide therapeutic and prevention efforts; and Prevention, supporting precision approaches to delay or avert disease progression. In collaboration with Gates Ventures, she also directs the Diagnostics Accelerator, advancing cutting-edge tools and biomarkers to reshape dementia care. Under her leadership, ADDF leverages venture philanthropy, global collaboration, and scientific rigor to catalyze breakthroughs and drive the next era of precision medicine for Alzheimer’s and related dementias.

Dr. Nisenbaum brings over 30 years of experience spanning biotechnology, industry, and academia. Prior to ADDF, she was the Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen and spent 20 years at Eli Lilly, where she held leadership roles in translational medicine, preclinical discovery, and early clinical development. Earlier in her career, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in neuroscience at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at NIH and the University of Tennessee, and a faculty position at the University of Connecticut. She has contributed to the development of more than 15 novel therapeutics, including three FDA-approved drugs.

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Lisa Ricciardi

President & CEO, Cognition Therapeutics, Inc.

Lisa Ricciardi has served as Cognition's president and CEO since March 2020 and as a member of our board of directors since March 2019. Lisa has deep experience in both large pharma and early stage companies. She previously served as SVP of global corporate and business development of Foundation Medicine, and as SVP of U.S. and international business development of Medco. In each role, she orchestrated successful M&A exits. Earlier in her career, Ms. Ricciardi was in the commercial division of Pfizer Inc., where she managed the launch of three drugs, before being appointed by the chairman to run global business development.

Ms. Ricciardi previously served on the boards of Contrafect (Nasdaq: CFRX), Chimerix (Nasdaq: CMRX), United Drug Healthcare Group, PLC (LSE: UDG) and Sepracor (Nasdaq: SEPR). In 2020, she was appointed executive in residence at Columbia Technology Ventures.

Ms. Ricciardi earned a Bachelor of Arts degree cum laude in English and religion from Wesleyan University and an MBA from the University of Chicago Booth School of Management.

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Manuel López-Figueroa

Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortium

Manuel López-Figueroa, Ph.D. is a neuroscientist, biotechnology executive, and investor with more than 25 years of experience spanning scientific research, venture capital, company formation, and strategic development in the life sciences.

Dr. López-Figueroa serves as Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research initiative involving Stanford University, the University of Michigan, Cornell University, the HudsonAlpha Institute for Biotechnology, and the University of California, Irvine.

Dr. López-Figueroa spent 25 years at Bay City Capital, a life sciences venture capital firm that has invested more than $1.6 billion across over 100 companies worldwide, where he served as Managing Director. His venture capital activities includes a more recent role as Operating Partner at Civilization Ventures, an early-stage investment firm focused on biotechnology and healthcare innovation.

He also serves as Lead Director and Chair of the Compensation and Nominations Committee of Oryzon Genomics (ORY.MC), a publicly traded biopharmaceutical company developing novel epigenetic therapies for central nervous system disorders and oncology.

Previously, Dr. López-Figueroa served as Chief Operating Officer of IMIDomics, a biotechnology company focused on immune-mediated inflammatory diseases that was acquired by UCB in 2026.

Dr. López-Figueroa completed his postdoctoral training at the University of Michigan and the University of Copenhagen. He holds a Ph.D. in Medicine and Surgery and an M.S. in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, respectively. He has also served on the boards of Zulia Biotech and Cantero Therapeutics, a BridgeBio Pharma subsidiary.

The Neuropsychiatry Renaissance Panel: New Targets, New TherapiesSun, 10 Jan

Marianne Mertens

Partner, Apollo Health Ventures

Profile coming soon...

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Matt Adams

CEO, BrainScope Company Inc.

Profile coming soon...

New Directions in Neurotechnology Panel: Devices, Therapeutics & WellnessSun, 10 Jan

Murali Gopalakrishnan

Global Head, Neuroscience Search & Evaluation, Corporate Strategy Office, AbbVie, Inc.

Murali Gopalakrishnan has responsibility for Neuroscience Search & Evaluation in Corporate Strategy Office at AbbVie. In prior roles, Murali held positions of increasing responsibility at Abbott / AbbVie leading discovery research programs across therapeutic areas including neuroscience, pain, nephrology and urology leading to the delivery of multiple clinical candidates to the R&D pipeline. At Abbott, Murali also led the Global External Research group & had responsibility for the China R&D Center in Shanghai while leading the Renal Discovery Research. He currently leads AbbVie's Neuroscience Search and Evaluation Group responsible for advancing external innovation opportunities across AbbVie's neuroscience areas of interest including psychiatry, neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's diseases, ALS etc.) and migraine/pain. Murali obtained his undergraduate training in pharmacy, PhD in Pharmacology with post-doctoral training in molecular biology and also holds an M.B.A degree.

Neuroscience Dealmaking Panel: What's Next for 2027Sun, 10 Jan

Peng Leong

CBO & Head of Brain Aging, BioAge Labs, Inc.

Dr. Peng Leong is Chief Business Officer at BioAge where he leads efforts to execute strategic transactions from ideation to close that convert prioritized drug targets into a portfolio of therapies for treating diseases of aging. Peng played an essential role in building BioAge, establishing partnerships with Amgen, Lilly and Novartis that enabled rapid growth of the Company’s drug pipeline. In previous industry roles, he led the acquisition or sale of over $1 billion in product rights across roles at Kazia Therapeutics, Merck KGaA, and DRI Healthcare. Early in his career, Peng was a healthcare investment banker at CIBC World Markets and Piper Jaffray. He holds a PhD in Biochemistry from the University of Toronto and an MBA from UC Berkeley.

Longevity Meets Neuroscience Panel: Where Investors Are Looking NextSun, 10 Jan

Ryan Dawes

Corporate Development | Search & Evaluation Neuroscience, Biogen

Profile coming soon...

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Sahil Kirpekar

CEO, Reunion Neuroscience, Inc.

Sahil Kirpekar, M.D., is an accomplished leader with more than two decades of experience in the health sciences. He is currently President and CEO of Reunion Neuroscience, where he’s helping guide the company as it seeks to maximize the potential of luvesilocin for patients across multiple indications and moves closer towards achieving its vision of becoming a differentiated psychiatry franchise.

Prior to joining Reunion, Sahil served as Chief Business Officer at atai Life Sciences (now AtaiBeckley), where he led multiple strategic transactions, investments, and acquisitions, including the acquisition of Beckley Psytech, and served on several public and private company boards. Previously, he spent more than eight years at Otsuka Pharmaceutical, including as Global Head of Business Development, where he was responsible for global therapeutic area and partnering strategy and executed transactions across CNS, immunology, nephrology, rare diseases, and oncology.

He has previously held commercial leadership roles launching specialty drugs and developing global commercial strategies. Across his career, Sahil has been responsible for transactions totaling several billion dollars in aggregate value, spanning early research collaborations to late-stage and commercial-stage assets. He is a physician by training and holds an MPhil from the University of Cambridge.

Psychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

Seth Lederman

Chairman & CEO, Tonix Pharmaceuticals Holding Corp.

Seth Lederman is a physician, scientist, drug-hunter, biopharmaceutical executive, and a co-founder of Tonix Pharmaceuticals. Prior to Tonix, Dr. Lederman founded Targent Pharmaceuticals, which developed late-stage oncology drugs, including levoleucovorin. After Spectrum Pharmaceuticals acquired Targent’s assets, levoleucovorin was marketed as Fusilev® for advanced colorectal cancer, gaining significant market acceptance.

Prior to becoming a biopharma executive, Dr. Lederman served as an Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious disease and the development of therapeutics for autoimmune diseases. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3.

In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital for several years. Dr. Lederman earned his MD from Columbia University’s College of Physicians and Surgeons and an AB from Princeton in Chemistry cum laude.

The Neuropsychiatry Renaissance Panel: New Targets, New TherapiesSun, 10 Jan

Spring Behrouz

CEO, Vincere Biosciences Inc.

Spring Behrouz, PhD, is a neuroscientist, translational biologist, and biotechnology entrepreneur dedicated to advancing disease-modifying therapies for Parkinson’s disease (PD) and related neurodegenerative disorders. As Co-Founder and CEO of Vincere Biosciences, she leads discovery and development of first-in-class small molecules that enhance mitophagy and improve mitochondrial quality control.

Dr. Behrouz’s commitment to PD spans more than two decades in academia (Mayo Clinic and Michigan State), academia-large pharma collaborations (Pfizer and Lundbeck), and biotech (NI and Vincere). She co-founded Neuroinitiative which focused on creating predictive modeling, network analytics, simulation platforms, virtual screening workflows, and AI/ML diagnostic tools that accelerate early drug discovery. These computational innovations ultimately catalyzed the creation of Vincere Biosciences. Under Dr. Behrouz’s leadership, Vincere has designed and advanced potent USP30 inhibitor small molecules that restore mitochondrial repair and support neuronal resilience.

Dr. Behrouz has secured more than $20 million in combined equity and non-dilutive funding. She has overseen complex multidisciplinary programs, recruited high-performing scientific teams, and executed discovery-to-clinical strategies on aggressive timelines. Her leadership has been recognized through awards and distinctions from organizations such as Johnson & Johnson, Bristol Myers Squibb, Biotech Week Boston, One Spark, and the Entrepreneurship World Cup.

Dr. Behrouz’s long-term mission is to translate discoveries in aging biology, particularly in neurodegeneration, to patients that desperately need disease modifying therapies.

Progress in PD, Movement Disorders & Related Conditions PanelSun, 10 Jan

Stephen Zicha

Neuroscience - Search and Evaluation, Eli Lilly and Company

Profile coming soon...

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 Jan

Steven Dickman

CEO, CBT Advisors

CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for more than twenty-five years. He founded CBT Advisors in 2003 and has worked on storytelling and strategy with nearly five hundred private biotechnology and life sciences clients. Much of the firm’s work focuses on drafting business sections for NASDAQ IPOs. More than one hundred clients have gone public, raising more than $13 billion. Previously, Steve was a venture capitalist with TVM Capital.

Psychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

Sumant Kulkarni

Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC

Sumant Kulkarni joined Canaccord Genuity in 2017 as a New York-based Managing Director covering Biotechnology stocks. His research focus is on biotech companies within the neuroscience space, where he was among the first analysts on Wall Street to specialize in this therapeutic area. Prior to joining Canaccord Genuity, Sumant was at Bank of America-Merrill Lynch where he covered biopharmaceutical stocks for over a decade as part of a top Institutional Investor-ranked team, and he was most recently a Director leading that firm’s Specialty Pharmaceuticals vertical. He started his career on the sell-side covering the Life Science Services sector at Jefferies.

Over the years, Sumant has become known for his in-depth biopharma knowledge that spans therapeutic areas/modalities, ability to boil down complex scientific concepts in terms of what they might mean for stocks, identifying stocks of under-followed companies, and applying a consistent/disciplined approach in his financial analyses. Sumant’s background includes an MBA, an MS in chemical engineering and academic research in biomedical engineering (with a focus in oncology and cardiology) from The Ohio State University, and a bachelor’s degree in chemical engineering from Bangalore University, India.

Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & DiagnosticsSun, 10 JanPsychedelics 2027 Panel: Where Does the Field StandSun, 10 Jan

SACHS ASSOCIATES SWITZERLAND AG

Aeschenvorstadt 4
Basel | CH-4051
Switzerland

SACHS ASSOCIATES LTD.

3rd floor, 89-90 Paul Street
London | EC2A 4NE
United Kingdom
Privacy Policy

© COPYRIGHT 2026. ALL RIGHTS RESERVED.